Disopyramide is an antiarrhythmic agent which the manufacturers claim to be effective in controlling both atrial and ventricular arrhythmias; recent promotion particularly emphasises the latter. It is marketed for oral use as the base (Rythmodan - Roussel) and as the phosphate (Norpace - Searle), but these preparations do not differ clinically and represent another example of pseudo-competition.1 For i. v. use Rythmodan is also marketed as the phosphate, no preparation of Norpace for i. v. use is available. When we discussed the drug four years ago2 there was insufficient evidence to recommend disopyramide for clinical use.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.